

ElÃ-sabeth PÃ©rez Ruiz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1054906/publications.pdf>

Version: 2024-02-01

81
papers

1,802
citations

448610

19
h-index

325983

40
g-index

84
all docs

84
docs citations

84
times ranked

3810
citing authors

#	ARTICLE	IF	CITATIONS
1	Genes Involved in Immune Reinduction May Constitute Biomarkers of Response for Metastatic Melanoma Patients Treated with Targeted Therapy. <i>Biomedicines</i> , 2022, 10, 284.	1.4	2
2	Impact of weight loss on cancer patients' quality of life at the beginning of the chemotherapy. <i>Supportive Care in Cancer</i> , 2021, 29, 627-634.	1.0	14
3	Incidence of COVID-19 in outpatients with cancer receiving active treatment in the context of a pandemic: An Andalusian cohort study. <i>Seminars in Oncology</i> , 2021, 48, 145-151.	0.8	3
4	SEOM clinical guideline for the management of cutaneous melanoma (2020). <i>Clinical and Translational Oncology</i> , 2021, 23, 948-960.	1.2	22
5	Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC). <i>Journal of Clinical Oncology</i> , 2011, 29, 463-475.	10.784314	95
6	1456P Impact of early palliative care in quality at the end of life in small cell lung cancer patients. <i>Annals of Oncology</i> , 2021, 32, S1081.	0.6	0
7	187P Relationship between immune profile and immunophenotype in early breast cancer. <i>Annals of Oncology</i> , 2021, 32, S439.	0.6	0
8	Liquid Biopsy as a Tool for the Characterisation and Early Detection of the Field Cancerization Effect in Patients with Oral Cavity Carcinoma. <i>Biomedicines</i> , 2021, 9, 1478.	1.4	3
9	Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies. <i>Drug Resistance Updates</i> , 2020, 53, 100718.	6.5	103
10	Tipifarnib in recurrent, metastatic HRAS mutant salivary gland cancer. <i>Cancer</i> , 2020, 126, 3972-3981.	2.0	34
11	Impact of intestinal dysbiosis-related drugs on the efficacy of immune checkpoint inhibitors in clinical practice. <i>Clinical and Translational Oncology</i> , 2020, 22, 1778-1785.	1.2	10
12	Monitoring through flow cytometry as a biomarker of early response to checkpoint inhibitor. <i>Journal of Clinical Oncology</i> , 2020, 38, e21603-e21603.	0.8	0
13	Abstract PO-024: Incidence of SARS-COV-2 infection in cancer patients undergoing active treatment. , 2020, , .		0
14	Influence of first treatment delay on survival among breast cancer subtypes. <i>Annals of Oncology</i> , 2019, 30, v83-v84.	0.6	0
15	Differences in survival between right and left-sided colorectal cancer (CRC) in every stage, a CARESS-CCR group study. <i>Annals of Oncology</i> , 2019, 30, v224.	0.6	0
16	Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells. <i>Onc Immunology</i> , 2019, 8, e1599636.	2.1	20
17	Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. <i>Nature</i> , 2019, 569, 428-432.	13.7	313
18	Genetic Susceptibility in Head and Neck Squamous Cell Carcinoma in a Spanish Population. <i>Cancers</i> , 2019, 11, 493.	1.7	15

#	ARTICLE	IF	CITATIONS
19	Clinical and sociodemographic factors that may influence the resilience of women surviving breast cancer: cross-sectional study. <i>Supportive Care in Cancer</i> , 2019, 27, 1279-1286.	1.0	15
20	SEOM clinical guidelines to primary prevention of cancer (2018). <i>Clinical and Translational Oncology</i> , 2019, 21, 106-113.	1.2	7
21	Impact of prophylactic TNF blockade in the dual PD-1 and CTLA-4 immunotherapy efficacy and toxicity. <i>Cell Stress</i> , 2019, 3, 236-239.	1.4	17
22	First hospital contact via the Emergency Department is an independent predictor of overall survival and disease-free survival in patients with colorectal cancer. <i>Revista Espanola De Enfermedades Digestivas</i> , 2019, 111, 750-756.	0.1	1
23	Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883401774974.	1.4	200
24	Co-stimulation Agonists via CD137, OX40, GITR, and CD27 for Immunotherapy of Cancer. , 2018, , 429-446.		0
25	Expression and Prognostic Value of Oestrogen Receptor Beta in Colorectal Cancer. <i>Pathology and Oncology Research</i> , 2018, 24, 871-879.	0.9	4
26	Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice. <i>Clinical and Translational Oncology</i> , 2018, 20, 862-869.	1.2	3
27	Enhancement of antibody-dependent cellular cytotoxicity of cetuximab by a chimeric protein encompassing interleukin-15. <i>Oncolimmunology</i> , 2018, 7, e1393597.	2.1	20
28	Bcl-2 Inhibition to Overcome Resistance to Chemo- and Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3950.	1.8	106
29	International Symposium: Trailblazing in Cancer Immunotherapy, October 29-31, 2017, Pamplona, Spain. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1809-1813.	2.0	0
30	Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts. <i>Journal of Translational Medicine</i> , 2018, 16, .	1.8	2
31	Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types. <i>Annals of Oncology</i> , 2018, 29, 2121-2128.	0.6	74
32	High serum vascular endothelial growth factor C predicts better relapse-free survival in early clinically node-negative breast cancer. <i>Oncotarget</i> , 2018, 9, 28131-28140.	0.8	6
33	Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancers.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3076-3076.	0.8	0
34	Abstract LB-151: Prophylactic TNF± blockade unplugs toxicity and efficacy in immunotherapy anti-PD-1 + anti-CTLA-4 combinations. , 2018, , .		0
35	Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells. <i>Immunology and Cell Biology</i> , 2017, 95, 347-355.	1.0	160
36	Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program. <i>Clinical and Translational Oncology</i> , 2017, 19, 761-768.	1.2	12

#	ARTICLE	IF	CITATIONS
37	Anti-CD137 and PD-1/PD-L1 Antibodies En Route toward Clinical Synergy. <i>Clinical Cancer Research</i> , 2017, 23, 5326-5328.	3.2	33
38	Analysis of autophagy gene polymorphisms in Spanish patients with head and neck squamous cell carcinoma. <i>Scientific Reports</i> , 2017, 7, 6887.	1.6	24
39	Prospective Evaluation Of Patient-Centered Care In Short-Term Cancer Survivors, At One And Two Years Post Treatment, Through The Patient Assessment Of Chronic Illness Care Questionnaire. <i>Value in Health</i> , 2017, 20, A519.	0.1	0
40	P1.07-015 Interferon-Gamma (INFG) as a Biomarker to Guide Immune Checkpoint Blockade (ICB) in Cancer Therapy. <i>Journal of Thoracic Oncology</i> , 2017, 12, S2001.	0.5	0
41	Differences in survival (sv) and clinicopathologic characteristics (cpc) between right and left-sided colorectal cancer (CRC): A CARESS-CCR group study. <i>Annals of Oncology</i> , 2017, 28, v198-v199.	0.6	0
42	Interferon-gamma (INFG), an important marker of response to immune checkpoint blockade (ICB) in non-small cell lung cancer (NSCLC) and melanoma patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11504-11504.	0.8	7
43	Immunological Landscape and Clinical Management of Rectal Cancer. <i>Frontiers in Immunology</i> , 2016, 7, 61.	2.2	14
44	Germline genetic background contribution to metastatic dissemination in breast cancer extreme phenotype patients. <i>Annals of Oncology</i> , 2016, 27, vi546.	0.6	1
45	Concordance of KRAS, NRAS and BRAF status between primary colorectal tumors and paired metastasis (mts). <i>Annals of Oncology</i> , 2016, 27, vi176.	0.6	0
46	Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population. <i>Oral Oncology</i> , 2016, 63, 38-43.	0.8	21
47	Epidemiological characteristics of a Spanish cohort of patients diagnosed with squamous cell carcinoma of head and neck: distribution of risk factors by tumor location. <i>Clinical and Translational Oncology</i> , 2016, 18, 1114-1122.	1.2	12
48	Clusterin expression (CLU) as a prognostic marker in colorectal carcinoma (CCR).. <i>Journal of Clinical Oncology</i> , 2016, 34, 563-563.	0.8	0
49	Pembrolizumab expanded access program (EAP) in Spain: clinical activity.. <i>Journal of Clinical Oncology</i> , 2016, 34, e21029-e21029.	0.8	0
50	Evaluation Of Patient-Centered Care In Short-Term Cancer Survivors, Through The Patient Assessment Of Chronic Illness Care Questionnaire. <i>Value in Health</i> , 2015, 18, A491-A492.	0.1	1
51	2304 Polychemotherapy on patients with pancreatic carcinoma: Experience of four hospitals in Spain. <i>European Journal of Cancer</i> , 2015, 51, S433.	1.3	0
52	Cross-cultural adaptation, reliability and validity of the Spanish version of the Quality of Life in Adult Cancer Survivors (QLACS) questionnaire: application in a sample of short-term survivors. <i>Health and Quality of Life Outcomes</i> , 2015, 13, 182.	1.0	17
53	New cutaneous toxicities with generic docetaxel: are the excipients guilty?. <i>Supportive Care in Cancer</i> , 2015, 23, 1917-1923.	1.0	16
54	Correlation between serum levels of vascular endothelial growth factor-C and sentinel lymph node status in early breast cancer. <i>Tumor Biology</i> , 2015, 36, 9285-9293.	0.8	9

#	ARTICLE	IF	CITATIONS
55	Frequency and Characteristics of Familial Melanoma in Spain: The FAM-GEM-1 Study. PLoS ONE, 2015, 10, e0124239.	1.1	8
56	Blinded independent validation of the PAM50-based Chemo-Endocrine Sensitivity Predictor (CESP) in hormone receptor (HR)-positive/HER2-negative (HR+/HER2-) breast cancer following neoadjuvant chemotherapy (NAC).. Journal of Clinical Oncology, 2015, 33, 569-569.	0.8	0
57	Assessment of Treatment Response with Fulvestrant (F) 500 Mg in Standard Clinical Practice Through a Retrospective Study: Nct01509625. Annals of Oncology, 2014, 25, iv120.	0.6	0
58	The FAM-GEM-1 study: Frequency and characteristics of familial melanoma in Spain.. Journal of Clinical Oncology, 2014, 32, 9039-9039.	0.8	0
59	Primary leptomenigeal histiocytic sarcoma in a patient with a good outcome: a case report and review of the literature. Journal of Medical Case Reports, 2013, 7, 127.	0.4	15
60	The role and prognostic value of apoptosis in colorectal carcinoma. BMC Clinical Pathology, 2013, 13, 24.	1.8	27
61	The role of apoptosis in colorectal carcinogenesis and its prognostic value.. Journal of Clinical Oncology, 2013, 31, e22131-e22131.	0.8	0
62	Assessment of treatment response with fulvestrant (F) 500 mg in standard clinical practice through a retrospective study: NCT01509625.. Journal of Clinical Oncology, 2013, 31, e11583-e11583.	0.8	0
63	Involvement of K-RAS mutations and amino acid substitutions in the survival of metastatic colorectal cancer patients. Tumor Biology, 2012, 33, 1829-1835.	0.8	9
64	Has the time to come leave the "watch-and-wait" strategy in newly diagnosed asymptomatic follicular lymphoma patients?. BMC Cancer, 2012, 12, 210.	1.1	8
65	Immunohistochemical expression of cyclooxygenase-2 in patients with advanced cancer of the larynx who have undergone induction chemotherapy with the intention of preserving phonation. Clinical and Translational Oncology, 2012, 14, 682-688.	1.2	6
66	Role of estrogen receptor- β as prognostic factor in colorectal cancer.. Journal of Clinical Oncology, 2012, 30, e14115-e14115.	0.8	0
67	Involvement of K-RAS mutations and amino acid substitutions in the survival of metastatic colorectal cancer patients.. Journal of Clinical Oncology, 2012, 30, e14116-e14116.	0.8	0
68	Impact of Epidermal Growth Factor Receptor Expression on Disease-Free Survival and Rate of Pelvic Relapse in Patients With Advanced Cancer of the Cervix Treated With Chemoradiotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 395-400.	0.6	21
69	Outcome of Small Invasive Breast Cancer with No Axillary Lymph Node Involvement. Breast Journal, 2011, 17, 32-38.	0.4	10
70	Limited impact of palliative chemotherapy on survival in advanced solid tumours in patients with poor performance status. Clinical and Translational Oncology, 2011, 13, 426-429.	1.2	24
71	Anti-Angiogenic Treatment (Sunitinib) for Disseminated Malignant Haemangiopericytoma: A Case Study and Review of the Literature. Case Reports in Oncology, 2011, 4, 55-59.	0.3	19
72	Prognosis of Microinvasive Breast Carcinoma with Negative Axillary Nodes in Accordance with TNM Classification Criteria. Breast Journal, 2010, 16, 669-671.	0.4	5

#	ARTICLE	IF	CITATIONS
73	Bevacizumab plus Low-Dose Metronomic Oral Cyclophosphamide in Heavily Pretreated Patients with Recurrent Ovarian Cancer. <i>Oncology</i> , 2010, 79, 98-104.	0.9	50
74	Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated recurrent ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2010, 28, e15507-e15507.	0.8	2
75	Response to paclitaxel in a radiotherapy-induced breast angiosarcoma. <i>Acta OncolĀgica</i> , 2009, 48, 1078-1079.	0.8	26
76	Aromatase Inhibitors As Adjuvant Therapy for Breast Cancer: Overall Survival Versus Disease-Free Survival As a Primary End Point in Clinical Practice. <i>Journal of Clinical Oncology</i> , 2009, 27, e255-e256.	0.8	0
77	Second complete remission induced by cyclophosphamide plus bevacizumab in two patients with heavily pre-treated ovarian cancer. <i>Clinical and Translational Oncology</i> , 2009, 11, 329-331.	1.2	6
78	Current status of anti-angiogenic agents in the treatment of ovarian carcinoma. <i>Clinical and Translational Oncology</i> , 2009, 11, 589-595.	1.2	19
79	Targeted therapy of metastatic breast cancer. <i>Clinical and Translational Oncology</i> , 2009, 11, 643-650.	1.2	31
80	Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer. <i>Clinical and Translational Oncology</i> , 2008, 10, 583-586.	1.2	60
81	Maintenance treatment in metastatic breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1907-1912.	1.1	39